Edward Brennan has served as a medical director at Wyeth-Ayerst Research and GlaxoSmithKline
Inc () (OTCQB:FSDDF) (FRA:0K9) has named veteran pharmaceutical executive Edward Brennan Jr. as president of its biosciences division.
Brennan has served as a medical director at Wyeth-Ayerst Research and GlaxoSmithKline, where he oversaw ten investigational new drug applications with the US Food and Drug Administration.
He also founded IndiPharm, a full-service clinical research organization that was later acquired by a private equity company.
READ: FSD Pharma strikes deal with Solarvest BioEnergy to develop pharmaceutical-grade cannabinoids from algae
“Ed is an accomplished biopharmaceutical executive with a proven track record in FDA submissions and drug development,” CEO Raza Bokhari said. “We aim to capitalize on his expert guidance as FSD builds on our recently announced acquisition of Prismic Pharmaceuticals and continues to execute on our strategy to identify and acquire cannabinoid-based pharmaceutical R&D companies focused on FDA approved clinical trials.”
is a Toronto-based producer of pharmaceutical-grade cannabis. On April 23, it announced a C$23.4 million acquisition of Prismic, a US pharmaceutical company focused on developing non-addictive drugs to combat the opioid epidemic.
Shares slipped 2.3% to C$0.22 on the CSE and 0.6% to US$0.16 on OTC markets.
Contact Andrew Kessel at [email protected]
Follow him on @andrew_kessel
CSE:HUGE
Market: CSE
Market Cap: $63.39 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer...
FOR OUR FULL DISCLAIMER CLICK HEREMost read
FSD Pharma rings the Nasdaq opening bell in 'exciting and momentous moment'
FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE) CEO Raza Bokhari, who runs the pharmaceutical cannabis research company, rang the Nasdaq opening bell together with with members of the board, leadership team, early investors, and others. Bokhari says it was an 'exciting and momentous moment' for the...
1 week, 2 days ago
2 min read
Prev article
3 min read
